{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:44:14Z","timestamp":1791081854614,"version":"4.1.0"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"10","funder":[{"name":"Assistance Publique \u2013 Hopitaux de Marseille"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Pretreatment with a loading dose (LD) of clopidogrel or ticagrelor before percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) is supported by the guidelines, but debated following a recent meta-analysis on clopidogrel pretreatment and the ACCOAST trial. In this trial prasugrel pretreatment failed to reduce ischaemic events. The timing of optimal platelet reactivity (PR) inhibition of ticagrelor and prasugrel in non ST-elevation ACS (NSTE ACS) is yet undetermined. In the present study, we aimed to investigate the delay required to reach optimal PR inhibition in NSTE ACS following a LD of ticagrelor or prasugrel. Consecutive patients undergoing PCI for NSTE ACS were randomised in this monocentre study. The Vasodilatorphosphoprotein index (VASP) was used to measure PR before the LD and then at 30 minutes, 1, 2, 4 and 24 hours (h) post-LD. Optimal PR inhibition was defined as a VASP&lt; 50 %. We randomised 24 patients to ticagrelor or prasugrel LD. One hour after the LD, 29 % of patients had a VASP &gt; 50 % (ticagrelor and prasugrel: 25 vs 33 %; p=0.7). Optimal PR inhibition was obtained 2 h after the LD in both groups (12\/12 with ticagrelor and 11\/12 with prasugrel). At that time, the mean VASP index was 19 \u00b1 16 % (95 %CI: 12\u201325). Maximal PR inhibition was reached after 4 h: 11 \u00b1 10 % (95 %CI: 6\u201315). In NSTE ACS undergoing PCI a LD of ticagrelor or prasugrel given during the procedure provides optimal P2Y12-ADP receptor blockade in 2 h and maximal inhibition within 4 h.<\/jats:p>","DOI":"10.1160\/th15-02-0149","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T02:33:52Z","timestamp":1440642832000},"page":"702-707","source":"Crossref","is-referenced-by-count":14,"title":["Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome"],"prefix":"10.1160","volume":"114","author":[{"given":"Marc","family":"Laine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Camoin-Jau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Noirot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Guieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Dignat-George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Paganelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Frere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"key":"10.1160\/TH15-02-0149-1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604253341702"},{"key":"10.1160\/TH15-02-0149-2","doi-asserted-by":"crossref","unstructured":"Mehta SR, Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000; 21: 2033-2041","DOI":"10.1053\/euhj.2000.2474"},{"key":"10.1160\/TH15-02-0149-3","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000160869.75810.98"},{"key":"10.1160\/TH15-02-0149-4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.101"},{"key":"10.1160\/TH15-02-0149-5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"},{"key":"10.1160\/TH15-02-0149-6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu278"},{"key":"10.1160\/TH15-02-0149-7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"10.1160\/TH15-02-0149-8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"10.1160\/TH15-02-0149-9","doi-asserted-by":"crossref","unstructured":"Bellemain-Appaix A, O\u2019Connor SA, Silvain J, et al.; ACTION Group. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Am Med Assoc 2012; 308: 2507-2516","DOI":"10.1001\/jama.2012.50788"},{"key":"10.1160\/TH15-02-0149-10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308075"},{"key":"10.1160\/TH15-02-0149-11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407024"},{"key":"10.1160\/TH15-02-0149-12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.024"},{"key":"10.1160\/TH15-02-0149-13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323"},{"key":"10.1160\/TH15-02-0149-14","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-02-0086"},{"key":"10.1160\/TH15-02-0149-15","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-03-0203"},{"key":"10.1160\/TH15-02-0149-16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.740324"},{"key":"10.1160\/TH15-02-0149-17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.912550"},{"key":"10.1160\/TH15-02-0149-18","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-02-0125"},{"key":"10.1160\/TH15-02-0149-19","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-03-0185"},{"key":"10.1160\/TH15-02-0149-20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.11.088"},{"key":"10.1160\/TH15-02-0149-21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.05.033"},{"key":"10.1160\/TH15-02-0149-22","doi-asserted-by":"crossref","unstructured":"Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2014; Epub ahead of print","DOI":"10.1161\/CIRCINTERVENTIONS.114.001593"},{"key":"10.1160\/TH15-02-0149-23","doi-asserted-by":"crossref","unstructured":"Lemesle G, Schurtz G, Bauters C, et al. High on-treatment platelet reactivity with Ticagrelor versus Prasugrel: a systematic review and meta-analysis. J Thromb Haemost 2015; Epub ahead of print","DOI":"10.1111\/jth.12907"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH15-02-0149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T05:15:13Z","timestamp":1521522913000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH15-02-0149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,11,24]]},"published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1160\/th15-02-0149","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}